Clinical Reviews in Allergy & Immunology

, Volume 38, Issue 2–3, pp 148–155 | Cite as

Mold and Human Health: Separating the Wheat from the Chaff

  • H. David Pettigrew
  • Carlo F. Selmi
  • Suzanne S. Teuber
  • M. Eric Gershwin
Article

Abstract

The term “mold” is utilized to define the ubiquitous fungal species commonly found in household dust and observed as visible multicellular filaments. Several well-defined human diseases are known to be caused or exacerbated by mold or by exposure to their byproducts. Among these, a solid connection has been established with infections, allergic bronchopulmonary aspergillosis, allergic fungal rhinosinusitis, hypersensitivity pneumonitis, and asthma. In the past decades, other less-defined and generally false conditions have also been ascribed to mold. We will herein review and critically discuss the available evidence on the influence of mold on human health.

Keywords

Mold Human diseases Fungi kingdom 

References

  1. 1.
    Richard JL (2007) Some major mycotoxins and their mycotoxicoses—an overview. Int J Food Microbiol 119:3–10CrossRefPubMedGoogle Scholar
  2. 2.
    Boermans HJ, Leung MC (2007) Mycotoxins and the pet food industry: toxicological evidence and risk assessment. Int J Food Microbiol 119:95–102CrossRefPubMedGoogle Scholar
  3. 3.
    Stenske KA, Smith JR, Newman SJ, Newman LB, Kirk CA (2006) Aflatoxicosis in dogs and dealing with suspected contaminated commercial foods. J Am Vet Med Assoc 228:1686–1691CrossRefPubMedGoogle Scholar
  4. 4.
    Henghold WB 2nd (2004) Other biologic toxin bioweapons: ricin, staphylococcal enterotoxin B, and trichothecene mycotoxins. Dermatol Clin 22:257–262 vCrossRefPubMedGoogle Scholar
  5. 5.
    Roponen M, Seuri M, Nevalainen A, Hirvonen MR (2002) Fungal spores as such do not cause nasal inflammation in mold exposure. Inhal Toxicol 14:541–549CrossRefPubMedGoogle Scholar
  6. 6.
    Schleibinger H, Laussmann D, Bornehag CG, Eis D, Rueden H (2008) Microbial volatile organic compounds in the air of moldy and mold-free indoor environments. Indoor Air 18:113–124CrossRefPubMedGoogle Scholar
  7. 7.
    Hamill R (2001) Infectious Diseases: Mycotic. In: Tierney L, McPhee S, Papadakis M (eds) Current Medical Diagnosis and Treatment 2001. Lange Medical Books/McGraw-Hill, New York, pp 1481–1493Google Scholar
  8. 8.
    Bush RK, Portnoy JM, Saxon A, Terr AI, Wood RA (2006) The medical effects of mold exposure. J Allergy Clin Immunol 117:326–333CrossRefPubMedGoogle Scholar
  9. 9.
    Agarwal R (2009) Allergic bronchopulmonary aspergillosis. Chest 135:805–826CrossRefPubMedGoogle Scholar
  10. 10.
    Greenberger PA (2002) Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110:685–692CrossRefPubMedGoogle Scholar
  11. 11.
    Greenberger PA, Patterson R (1988) Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 81:646–650CrossRefPubMedGoogle Scholar
  12. 12.
    Seltzer JM, Fedoruk MJ (2007) Health effects of mold in children. Pediatr Clin North Am 54:309–333 viii-ixCrossRefPubMedGoogle Scholar
  13. 13.
    Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE (1977) Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 86:405–414PubMedGoogle Scholar
  14. 14.
    Luong A, Marple B (2005) The role of fungi in chronic rhinosinusitis. Otolaryngol Clin North Am 38:1203–1213CrossRefPubMedGoogle Scholar
  15. 15.
    Luong A, Marple BF (2004) Allergic fungal rhinosinusitis. Curr Allergy Asthma Rep 4:465–470CrossRefPubMedGoogle Scholar
  16. 16.
    Ryan MW, Marple BF (2007) Allergic fungal rhinosinusitis: diagnosis and management. Curr Opin Otolaryngol Head Neck Surg 15:18–22CrossRefPubMedGoogle Scholar
  17. 17.
    Manning SC, Holman M (1998) Further evidence for allergic pathophysiology in allergic fungal sinusitis. Laryngoscope 108:1485–1496CrossRefPubMedGoogle Scholar
  18. 18.
    Bent JP 3rd, Kuhn FA (1994) Diagnosis of allergic fungal sinusitis. Otolaryngol Head Neck Surg 111:580–588CrossRefPubMedGoogle Scholar
  19. 19.
    Ebbens FA, Fokkens WJ (2008) The mold conundrum in chronic rhinosinusitis: where do we stand today? Curr Allergy Asthma Rep 8:93–101CrossRefPubMedGoogle Scholar
  20. 20.
    Ebbens FA, Georgalas C, Fokkens WJ (2009) Fungus as the cause of chronic rhinosinusitis: the case remains unproven. Curr Opin Otolaryngol Head Neck Surg 17:43–49CrossRefPubMedGoogle Scholar
  21. 21.
    Ebbens FA, Scadding GK, Badia L, Hellings PW, Jorissen M, Mullol J, Cardesin A, Bachert C, van Zele TP, Dijkgraaf MG, Lund V, Fokkens WJ (2006) Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 118:1149–1156CrossRefPubMedGoogle Scholar
  22. 22.
    Kennedy DW, Kuhn FA, Hamilos DL, Zinreich SJ, Butler D, Warsi G, Pfister PJ, Tavakkol A (2005) Treatment of chronic rhinosinusitis with high-dose oral terbinafine: a double blind, placebo-controlled study. Laryngoscope 115:1793–1799CrossRefPubMedGoogle Scholar
  23. 23.
    Weschta M, Rimek D, Formanek M, Polzehl D, Podbielski A, Riechelmann H (2004) Topical antifungal treatment of chronic rhinosinusitis with nasal polyps: a randomized, double-blind clinical trial. J Allergy Clin Immunol 113:1122–1128CrossRefPubMedGoogle Scholar
  24. 24.
    Girard M, Lacasse Y, Cormier Y (2009) Hypersensitivity pneumonitis. Allergy 64:322–334CrossRefPubMedGoogle Scholar
  25. 25.
    Kurup VP, Zacharisen MC, Fink JN (2006) Hypersensitivity pneumonitis. Indian J Chest Dis Allied Sci 48:115–128PubMedGoogle Scholar
  26. 26.
    Baur X (1995) Hypersensitivity pneumonitis (extrinsic allergic alveolitis) induced by isocyanates. J Allergy Clin Immunol 95:1004–1010CrossRefPubMedGoogle Scholar
  27. 27.
    Yoshizawa Y, Ohtsuka M, Noguchi K, Uchida Y, Suko M, Hasegawa S (1989) Hypersensitivity pneumonitis induced by toluene diisocyanate: sequelae of continuous exposure. Ann Intern Med 110:31–34PubMedGoogle Scholar
  28. 28.
    Harrison LC, Honeyman MC, Morahan G, Wentworth JM, Elkassaby S, Colman PG, Fourlanos S (2008) Type 1 diabetes: lessons for other autoimmune diseases? J Autoimmun 31:306–310CrossRefPubMedGoogle Scholar
  29. 29.
    Rieger R, Gershwin ME (2007) The X and why of xenobiotics in primary biliary cirrhosis. J Autoimmun 28:76–84CrossRefPubMedGoogle Scholar
  30. 30.
    Richerson HB, Bernstein IL, Fink JN, Hunninghake GW, Novey HS, Reed CE, Salvaggio JE, Schuyler MR, Schwartz HJ, Schwartz HJ, Stechschulte DJ (1989) Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the Subcommittee on Hypersensitivity Pneumonitis. J Allergy Clin Immunol 84:839–844CrossRefPubMedGoogle Scholar
  31. 31.
    Monkare S, Haahtela T (1987) Farmer’s lung—a 5-year follow-up of eighty-six patients. Clin Allergy 17:143–151CrossRefPubMedGoogle Scholar
  32. 32.
    Delfino RJ, Zeiger RS, Seltzer JM, Street DH, Matteucci RM, Anderson PR, Koutrakis P (1997) The effect of outdoor fungal spore concentrations on daily asthma severity. Environ Health Perspect 105:622–635CrossRefPubMedGoogle Scholar
  33. 33.
    Black PN, Udy AA, Brodie SM (2000) Sensitivity to fungal allergens is a risk factor for life-threatening asthma. Allergy 55:501–504CrossRefPubMedGoogle Scholar
  34. 34.
    Bush RK, Prochnau JJ (2004) Alternaria-induced asthma. J Allergy Clin Immunol 113:227–234CrossRefPubMedGoogle Scholar
  35. 35.
    O’Driscoll BR, Hopkinson LC, Denning DW (2005) Mold sensitization is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med 5:4CrossRefPubMedGoogle Scholar
  36. 36.
    Pulimood TB, Corden JM, Bryden C, Sharples L, Nasser SM (2007) Epidemic asthma and the role of the fungal mold Alternaria alternata. J Allergy Clin Immunol 120:610–617CrossRefPubMedGoogle Scholar
  37. 37.
    Denning DW, O’Driscoll BR, Hogaboam CM, Bowyer P, Niven RM (2006) The link between fungi and severe asthma: a summary of the evidence. Eur Respir J 27:615–626CrossRefPubMedGoogle Scholar
  38. 38.
    Neukirch C, Henry C, Leynaert B, Liard R, Bousquet J, Neukirch F (1999) Is sensitization to Alternaria alternata a risk factor for severe asthma? A population-based study. J Allergy Clin Immunol 103:709–711CrossRefPubMedGoogle Scholar
  39. 39.
    Niedoszytko M, Chelminska M, Jassem E, Czestochowska E (2007) Association between sensitization to Aureobasidium pullulans (Pullularia sp) and severity of asthma. Ann Allergy Asthma Immunol 98:153–156CrossRefPubMedGoogle Scholar
  40. 40.
    Simon-Nobbe B, Denk U, Poll V, Rid R, Breitenbach M (2008) The spectrum of fungal allergy. Int Arch Allergy Immunol 145:58–86CrossRefPubMedGoogle Scholar
  41. 41.
    Dales RE, Cakmak S, Judek S, Dann T, Coates F, Brook JR, Burnett RT (2003) The role of fungal spores in thunderstorm asthma. Chest 123:745–750CrossRefPubMedGoogle Scholar
  42. 42.
    Belanger K, Beckett W, Triche E, Bracken MB, Holford T, Ren P, McSharry JE, Gold DR, Platts-Mills TA, Leaderer BP (2003) Symptoms of wheeze and persistent cough in the first year of life: associations with indoor allergens, air contaminants, and maternal history of asthma. Am J Epidemiol 158:195–202CrossRefPubMedGoogle Scholar
  43. 43.
    Gent JF, Ren P, Belanger K, Triche E, Bracken MB, Holford TR, Leaderer BP (2002) Levels of household mold associated with respiratory symptoms in the first year of life in a cohort at risk for asthma. Environ Health Perspect 110:A781–786PubMedGoogle Scholar
  44. 44.
    Andersson M, Downs S, Mitakakis T, Leuppi J, Marks G (2003) Natural exposure to Alternaria spores induces allergic rhinitis symptoms in sensitized children. Pediatr Allergy Immunol 14:100–105CrossRefPubMedGoogle Scholar
  45. 45.
    Gergen PJ, Turkeltaub PC (1992) The association of individual allergen reactivity with respiratory disease in a national sample: data from the second National Health and Nutrition Examination Survey, 1976–80 (NHANES II). J Allergy Clin Immunol 90:579–588CrossRefPubMedGoogle Scholar
  46. 46.
    Helbling A, Gayer F, Pichler WJ, Brander KA (1998) Mushroom (Basidiomycete) allergy: diagnosis established by skin test and nasal challenge. J Allergy Clin Immunol 102:853–858CrossRefPubMedGoogle Scholar
  47. 47.
    Rowe MS, Bailey J, Ownby DR (1986) Evaluation of the cause of nasal and ocular symptoms associated with lawn mowing. J Allergy Clin Immunol 77:714–719CrossRefPubMedGoogle Scholar
  48. 48.
    Katz Y, Verleger H, Barr J, Rachmiel M, Kiviti S, Kuttin ES (1999) Indoor survey of moulds and prevalence of mould atopy in Israel. Clin Exp Allergy 29:186–192CrossRefPubMedGoogle Scholar
  49. 49.
    Lander F, Meyer HW, Norn S (2001) Serum IgE specific to indoor moulds, measured by basophil histamine release, is associated with building-related symptoms in damp buildings. Inflamm Res 50:227–231CrossRefPubMedGoogle Scholar
  50. 50.
    Montealegre F, Meyer B, Chardon D, Vargas W, Zavala D, Hart B, Bayona M (2004) Comparative prevalence of sensitization to common animal, plant and mould allergens in subjects with asthma, or atopic dermatitis and/or allergic rhinitis living in a tropical environment. Clin Exp Allergy 34:51–58CrossRefPubMedGoogle Scholar
  51. 51.
    Reijula K, Leino M, Mussalo-Rauhamaa H, Nikulin M, Alenius H, Mikkola J, Elg P, Kari O, Makinen-Kiljunen S, Haahtela T (2003) IgE-mediated allergy to fungal allergens in Finland with special reference to Alternaria alternata and Cladosporium herbarum. Ann Allergy Asthma Immunol 91:280–287CrossRefPubMedGoogle Scholar
  52. 52.
    Scalabrin DM, Bavbek S, Perzanowski MS, Wilson BB, Platts-Mills TA, Wheatley LM (1999) Use of specific IgE in assessing the relevance of fungal and dust mite allergens to atopic dermatitis: a comparison with asthmatic and nonasthmatic control subjects. J Allergy Clin Immunol 104:1273–1279CrossRefPubMedGoogle Scholar
  53. 53.
    Boguniewicz M, Schmid-Grendelmeier P, Leung DY (2006) Atopic dermatitis. J Allergy Clin Immunol 118:40–43CrossRefPubMedGoogle Scholar
  54. 54.
    Leung DY (2000) Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105:860–876CrossRefPubMedGoogle Scholar
  55. 55.
    Casagrande BF, Fluckiger S, Linder MT, Johansson C, Scheynius A, Crameri R, Schmid-Grendelmeier P (2006) Sensitization to the yeast Malassezia sympodialis is specific for extrinsic and intrinsic atopic eczema. J Invest Dermatol 126:2414–2421CrossRefPubMedGoogle Scholar
  56. 56.
    Johansson C, Sandstrom MH, Bartosik J, Sarnhult T, Christiansen J, Zargari A, Back O, Wahlgren CF, Faergemann J, Scheynius A, Tengvall Linder M (2003) Atopy patch test reactions to Malassezia allergens differentiate subgroups of atopic dermatitis patients. Br J Dermatol 148:479–488CrossRefPubMedGoogle Scholar
  57. 57.
    Zargari A, Eshaghi H, Back O, Johansson S, Scheynius A (2001) Serum IgE reactivity to Malassezia furfur extract and recombinant M. furfur allergens in patients with atopic dermatitis. Acta Derm Venereol 81:418–422CrossRefPubMedGoogle Scholar
  58. 58.
    Elagin RB, Balijepalli S, Diacovo MJ, Baekkeskov S, Jaume JC (2009) Homing of GAD65 specific autoimmunity and development of insulitis requires expression of both DQ8 and human GAD65 in transgenic mice. J Autoimmun 33:50–57CrossRefPubMedGoogle Scholar
  59. 59.
    Gebe JA, Unrath KA, Yue BB, Miyake T, Falk BA, Nepom GT (2008) Autoreactive human T-cell receptor initiates insulitis and impaired glucose tolerance in HLA DR4 transgenic mice. J Autoimmun 30:197–206CrossRefPubMedGoogle Scholar
  60. 60.
    Hogan TV, Ang DK, Gleeson PA, van Driel IR (2008) Extrathymic mechanisms of T cell tolerance: lessons from autoimmune gastritis. J Autoimmun 31:268–273CrossRefPubMedGoogle Scholar
  61. 61.
    Jordan MA, Baxter AG (2008) The genetics of immunoregulatory T cells. J Autoimmun 31:237–244CrossRefPubMedGoogle Scholar
  62. 62.
    Maverakis E, Beech JT, Schneider S, Sercarz EE (2008) Presentation of a determinant by MHC class II can be prevented through competitive capture by a flanking determinant on a multideterminant peptide. J Autoimmun 31:59–65CrossRefPubMedGoogle Scholar
  63. 63.
    Morahan G, Peeva V, Mehta M, Williams R (2008) Systems genetics can provide new insights in to immune regulation and autoimmunity. J Autoimmun 31:233–236CrossRefPubMedGoogle Scholar
  64. 64.
    Pai S, Thomas R (2008) Immune deficiency or hyperactivity-Nf-kappab illuminates autoimmunity. J Autoimmun 31:245–251CrossRefPubMedGoogle Scholar
  65. 65.
    Papadimitraki ED, Bertsias GK, Boumpas DT (2007) Toll like receptors and autoimmunity: a critical appraisal. J Autoimmun 29:310–318PubMedGoogle Scholar
  66. 66.
    Poletaev AB, Stepanyuk VL, Gershwin ME (2008) Integrating immunity: the immunculus and self-reactivity. J Autoimmun 30:68–73CrossRefPubMedGoogle Scholar
  67. 67.
    Sanchez-Pernaute O, Ospelt C, Neidhart M, Gay S (2008) Epigenetic clues to rheumatoid arthritis. J Autoimmun 30:12–20CrossRefPubMedGoogle Scholar
  68. 68.
    Youinou P, Jamin C (2009) The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 32:206–210CrossRefPubMedGoogle Scholar
  69. 69.
    Chang C, Gershwin ME (2005) Mold hysteria: origin of the hoax. Clin Dev Immunol 12:151–158CrossRefPubMedGoogle Scholar
  70. 70.
    Terr AI (2009) Sick building syndrome: is mould the cause? Med Mycol 47(Suppl 1):S217–222CrossRefPubMedGoogle Scholar
  71. 71.
    Tsai YJ, Gershwin ME (2002) The sick building syndrome: what is it when it is? Compr Ther 28:140–144CrossRefPubMedGoogle Scholar
  72. 72.
    Redlich CA, Sparer J, Cullen MR (1997) Sick-building syndrome. Lancet 349:1013–1016CrossRefPubMedGoogle Scholar
  73. 73.
    Terr AI (2001) Stachybotrys: relevance to human disease. Ann Allergy Asthma Immunol 87:57–63CrossRefPubMedGoogle Scholar
  74. 74.
    Fatal fungus. (1998), Environ Health Perspect 106, A11-12.Google Scholar
  75. 75.
    Pestka JJ, Yike I, Dearborn DG, Ward MD, Harkema JR (2008) Stachybotrys chartarum, trichothecene mycotoxins, and damp building-related illness: new insights into a public health enigma. Toxicol Sci 104:4–26CrossRefPubMedGoogle Scholar
  76. 76.
    Johanning E, Biagini R, Hull D, Morey P, Jarvis B, Landsbergis P (1996) Health and immunology study following exposure to toxigenic fungi (Stachybotrys chartarum) in a water-damaged office environment. Int Arch Occup Environ Health 68:207–218PubMedGoogle Scholar
  77. 77.
    Hodgson MJ, Morey P, Leung WY, Morrow L, Miller D, Jarvis BB, Robbins H, Halsey JF, Storey E (1998) Building-associated pulmonary disease from exposure to Stachybotrys chartarum and Aspergillus versicolor. J Occup Environ Med 40:241–249CrossRefPubMedGoogle Scholar
  78. 78.
    Nordness ME, Zacharisen MC, Fink JN (2003) Toxic and other non-IgE-mediated effects of fungal exposures. Curr Allergy Asthma Rep 3:438–446CrossRefPubMedGoogle Scholar
  79. 79.
    Edmondson DA, Nordness ME, Zacharisen MC, Kurup VP, Fink JN (2005) Allergy and “toxic mold syndrome”. Ann Allergy Asthma Immunol 94:234–239CrossRefPubMedGoogle Scholar
  80. 80.
    Borchers AT, Chang C, Keen CL, Gershwin ME (2006) Airborne environmental injuries and human health. Clin Rev Allergy Immunol 31:1–101CrossRefPubMedGoogle Scholar
  81. 81.
    Acute pulmonary hemorrhage/hemosiderosis among infants—Cleveland, January 1993-November 1994. (1994), MMWR Morb Mortal Wkly Rep 43, 881-883Google Scholar
  82. 82.
    Update: pulmonary hemorrhage/hemosiderosis among infants—Cleveland, Ohio, 1993-1996. (1997), MMWR Morb Mortal Wkly Rep 46, 33-35Google Scholar
  83. 83.
    Etzel RA, Montana E, Sorenson WG, Kullman GJ, Allan TM, Dearborn DG, Olson DR, Jarvis BB, Miller JD (1998) Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med 152:757–762PubMedGoogle Scholar
  84. 84.
    Dearborn DG, Yike I, Sorenson WG, Miller MJ, Etzel RA (1999) Overview of investigations into pulmonary hemorrhage among infants in Cleveland, Ohio. Environ Health Perspect 107(Suppl 3):495–499PubMedGoogle Scholar
  85. 85.
    From the Centers for Disease Control and Prevention. Update: pulmonary hemorrhage/hemosiderosis among infants—Cleveland, Ohio, 1993–1996. (2000), JAMA 283, 1951–1953Google Scholar
  86. 86.
    Chapman JA, Terr AI, Jacobs RL, Charlesworth EN, Bardana EJ Jr (2003) Toxic mold: phantom risk vs science. Ann Allergy Asthma Immunol 91:222–232CrossRefPubMedGoogle Scholar
  87. 87.
    Babcock DW (2006) The legal implications of “toxic” mold exposure. J Environ Health 68:50–51PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • H. David Pettigrew
    • 1
  • Carlo F. Selmi
    • 1
    • 2
  • Suzanne S. Teuber
    • 1
  • M. Eric Gershwin
    • 1
  1. 1.Division of Rheumatology, Allergy and Clinical ImmunologyUniversity of California at Davis School of Medicine, Genome and Biomedical Sciences FacilityDavisUSA
  2. 2.Department of Translational Medicine, IRCCS-Istituto Clinico HumanitasUniversità degli Studi di MilanoRozzanoItaly

Personalised recommendations